Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancerMarc Peeters, R. Sidhu, Michel Ducreux et al.|Annals of Oncology|2013Cited by 220
KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated AnalysisMarc Peeters, Scott D. Patterson, Kelly S. Oliner et al.|Annals of Oncology|2014Cited by 3